XML 34 R24.htm IDEA: XBRL DOCUMENT
v3.25.2

Share-Based Payment Transactions | 12 Months Ended
--- | ---
Dec. 31, 2024
Share-Based Payment Transactions [Abstract] |
SHARE-BASED PAYMENT TRANSACTIONS |
NOTE 19:- | SHARE-BASED PAYMENT TRANSACTIONS
| a. | The cost of share-based payment recognized in the financial statements:
The expenses due to share-based compensation for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the Company is shown in the following table, detailed by departments:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Research and development expenses |  | $ | 45 |  |  | $ | 34 |  |  | $ | 264 |
General and administrative expenses |  |  | 524 |  |  |  | 162 |  |  |  | 633 |
|  | $ | 569 |  |  | $ | 196 |  |  | $ | 897 |
| 1. | The 2005 and 2015 ESOP and 2023 Plan of the Company:
On December 28, 2023, the Board adopted an additional new plan, the 2023 Share Incentive Plan (the “2023 Plan”). The Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under the 2015 ESOP remain outstanding and subject to the 2015 ESOP. Under the 2023 Plan, the Company may grant its employees and other service providers equity-based incentive awards (“Share Options”). On December 28, 2023, the Board approved to reserve for issuance under the 2023 Plan 47,619 Ordinary Shares.
| 2. | On January 3, 2022 (the “2022 Grant Date”), the Board approved the grant of 326 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company’s shareholders (the “2022 General Meeting”), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $3,549 per Share Option.
The fair value for Share Options granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:
|  | February 10, 2022 |  |  | January 3, 2022 |
Underlying ordinary share price |  |  | 2,724.54 |  |  |  | 3,674.58 |
Dividend yield (%) |  |  | 0 |  |  |  | 0 |
Expected volatility (%) |  |  | 133 |  |  |  | 134 |
Risk-free interest rate (%) |  |  | 2.00 |  |  |  | 1.46 |
Expected life of Share Options (years) |  |  | 6 |  |  |  | 6 |
The fair value of the Share Options granted on January 3, 2022, was set at $3,325.14 per Share Option, and the fair value of the Share Options granted on February 10, 2022, was set at $2,407.86 per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end at April 21, 2024. During the year ended December 31, 2024, share-based compensation in respect of Share Options of $7 was charged to the consolidated statements of comprehensive loss.
| 3. | During the year ended December 31, 2024, the Company issued consultants 30,770 ordinary shares in respect of services rendered. The shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $105.
| b. | Movement during the year:
| 1. | The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:
|  | Number of Share Options |  |  | Weighted average exercise price |
|  |  |  |  | USD |
2024: |  |  |  |  |  |  |  |
Share Options outstanding at the beginning of the year |  |  | 334 |  |  |  | 3,491.88 |
Share Options outstanding at the end of the year |  |  | 324 |  |  |  | 7,354.83 |
Share Options exercisable at the end of the year |  |  | 324 |  |  |  | 7,354.83 |
2023: |  |  |  |  |  |  |  |
Share Options outstanding at the beginning of the year |  |  | 336 |  |  |  | 3,488.94 |
Share Options cancelled during the year |  |  | (2 | ) |  |  | 3,035.55 |
Share Options outstanding at the end of the year |  |  | 334 |  |  |  | 3,491.88 |
Share Options exercisable at the end of the year |  |  | 279 |  |  |  | 3,477.18 |
| 2. | The weighted average remaining contractual life of the Share Options outstanding was 2.99 years and 4.03 years as of December 31, 2024, and 2023, respectively.
| 3. | The range of exercise prices of Share Options outstanding at the end of the year was $3,549 - $444,759 (inclusive) as of December 31, 2024, and 2023, respectively.
| c. | Restricted Share Units:
| 1 | On June 20, 2024, the Company granted 25,238 Restricted Share Units (“RSUs”) to directors and officers, pursuant to the Company’s RSU Plan. The RSUs will vest at each recipient’s discretion and taking into account personal tax implications and convert into 25,238 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on June 20, 2024, which was $18.753.
| 2 | On August 8, 2024, the Company granted 25,238 RSUs to directors and officers, pursuant to the Company’s RSU Plan. The RSUs will vest at each recipient’s discretion and taking into account personal tax implications and convert into 25,238 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August 8, 2024, which was $6.636.
RSU transactions for the year ended December 31, 2024, and for the year ended December 31, 2023, are as follows:
|  | Number |
Balance, January 1, 2024 |  |  | - |
RSUs granted |  |  | 50,476 |
Expiry of RSUs |  |  | - |
Exercise of RSUs |  |  | - |
Balance, December 31, 2024 |  |  | 50,476 |
Total exercisable RSUs as of December 31, 2024, are 12,619. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $456 was charged to the Consolidated Statements of Comprehensive Loss.

X
- Definition The entire disclosure for share-based payment arrangements. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 44 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration